MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-16-2026
Atara Biotherapeutics Market Cap 2011-2026 | ATRA
As of April 21, 2026 Atara Biotherapeutics has a market cap of $ 62.6 M
Capitalization is the market value of a company whose shares are traded on the stock exchange. It is calculated by multiplying the market price of a share by the total number of the company's shares. Capitalization indicates volatility, risk, and growth potential. This metric is often used for a quick assessment of a company’s investment profile.[1]
Capitalization is an important indicator for investors and analysts, as it helps determine the size and significance of a company in the stock market. Companies with large capitalization are considered more stable and reliable, as they have more resources and financial power to grow and survive in the market.
This metric can be divided into several categories: small (from 300 million to 2 billion dollars), medium (from 2 to 10 billion dollars), and large (over 10 billion dollars). Companies with different levels of capitalization have their own characteristics and risks, so investors usually take this indicator into account when making investment decisions.
Capitalization can also change over time depending on the share price and the number of shares in circulation. Therefore, it is a dynamic indicator that requires constant monitoring and analysis to make well-informed investment decisions.
Annual Market Cap Atara Biotherapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 73.6 M | 51 M | 2.92 M | 519 M | 1.48 B | 1.45 B | 698 M | 1.58 B | 1.2 B | 363 M | 463 M | 121 M | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.58 B | 2.92 M | 667 M |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.
Market Cap of other stocks in the Biotechnology industry
| Issuer | Market Cap | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
315 M | - | 2.43 % | $ 254 M |  Germany |
 |
Alterity Therapeutics Limited
ATHE
|
895 M | $ 5.15 | 15.21 % | $ 12.4 B |  Australia |
 |
Allakos
ALLK
|
114 M | - | - | $ 28.6 M |  USA |
 |
AlloVir
ALVR
|
13.1 M | - | 4.14 % | $ 49.1 M | USA |
 |
I-Mab
IMAB
|
127 M | - | - | $ 866 M |  China |
 |
Applied Molecular Transport
AMTI
|
22.1 M | - | - | $ 10.1 M | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
33.6 B | - | - | $ 40.3 B | USA |
 |
Applied Therapeutics
APLT
|
541 M | - | - | $ 8.42 M | USA |
 |
Aptinyx
APTX
|
9.48 M | - | -39.0 % | $ 4.57 M | USA |
 |
Genfit SA
GNFT
|
168 B | - | 2.54 % | $ 160 B |  France |
 |
Biophytis SA
BPTS
|
549 M | - | -13.47 % | $ 169 M | France |
 |
Advaxis
ADXS
|
1.87 M | - | -9.65 % | $ 45.9 M | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
28.9 M | - | -1.52 % | $ 24.7 M | USA |
 |
Akouos
AKUS
|
172 M | - | 0.23 % | $ 488 M | USA |
 |
Midatech Pharma plc
MTP
|
79 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Aligos Therapeutics
ALGS
|
65.9 M | $ 6.51 | -2.54 % | $ 64.4 M | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
1.25 B | $ 22.92 | 0.17 % | $ 1.07 B | USA |
 |
Avenue Therapeutics
ATXI
|
544 K | - | -52.27 % | $ 4.45 M | USA |
 |
BioNTech SE
BNTX
|
62.9 B | $ 105.19 | 2.21 % | $ 27.2 B | Germany |
 |
Aravive
ARAV
|
60.4 M | - | -13.39 % | $ 1.45 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
2.83 B | - | - | - |  Russia |
 |
Can-Fite BioPharma Ltd.
CANF
|
4.81 M | $ 3.0 | -1.32 % | $ 4.94 M |  Israel |
 |
Aeterna Zentaris
AEZS
|
41.4 M | - | 5.93 % | $ 314 M |  Canada |
 |
AstraZeneca PLC
AZN
|
81.2 B | - | - | $ 96.9 B | Britain |
 |
AgeX Therapeutics
AGE
|
14.1 K | - | -10.17 % | $ 12.2 K | USA |
 |
Brainstorm Cell Therapeutics
BCLI
|
6.33 M | - | -2.5 % | $ 5.88 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
724 M | - | - | $ 1.01 B | USA |
 |
Akebia Therapeutics
AKBA
|
334 M | $ 1.43 | 1.78 % | $ 368 M | USA |
 |
BioDelivery Sciences International
BDSI
|
308 M | - | -4.8 % | $ 255 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
7.72 M | - | - | $ 7.46 M | Israel |
 |
Applied Genetic Technologies Corporation
AGTC
|
32.8 M | - | - | $ 26.5 M | USA |
 |
BeiGene, Ltd.
BGNE
|
253 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Aquestive Therapeutics
AQST
|
467 M | $ 4.24 | -1.85 % | $ 453 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
3.44 B | $ 24.47 | -0.24 % | $ 3.11 B | USA |
 |
Burford Capital Limited
BUR
|
2.09 B | $ 4.99 | 0.6 % | $ 804 M | Britain |
 |
AIkido Pharma
AIKI
|
19.6 M | - | 1.93 % | $ 17.4 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
322 M | $ 1.58 | -1.25 % | $ 420 M | Britain |
 |
Aptose Biosciences
APTO
|
2.32 M | - | -45.71 % | $ 1.2 M | Canada |
 |
BioXcel Therapeutics
BTAI
|
15.4 M | $ 1.2 | 4.35 % | $ 14.6 M | USA |
 |
AVROBIO
AVRO
|
56.3 M | - | 1083.1 % | $ 745 M | USA |
 |
Cabaletta Bio
CABA
|
283 M | $ 3.31 | -3.92 % | $ 333 M | USA |
 |
bluebird bio
BLUE
|
67 M | - | - | $ 546 M | USA |
 |
Fennec Pharmaceuticals
FENC
|
169 M | $ 6.73 | -0.88 % | $ 192 M | USA |
 |
Akero Therapeutics
AKRO
|
3.25 B | - | - | $ 3.67 B | USA |
 |
CureVac N.V.
CVAC
|
3.53 B | - | - | $ 867 M | Germany |
 |
CymaBay Therapeutics
CBAY
|
3.43 B | - | - | $ 3.45 B | USA |
 |
Cidara Therapeutics
CDTX
|
148 M | - | - | $ 1.41 B | USA |
 |
ChromaDex Corporation
CDXC
|
431 M | - | -0.88 % | $ 598 M | USA |
 |
Allena Pharmaceuticals
ALNA
|
71.4 M | - | 3.16 % | $ 1.9 M | USA |
 |
ContraFect Corporation
CFRX
|
1.08 M | - | -5.16 % | $ 5.39 M | USA |